Login or sign up
For business
Average ratingAverage
3.9/ 5

Based on 9 reviews

533%
422%
344%
20%
10%
Ask AI

Questions about Vascugen

Based on 9 reviews, listing data and website checks · updated 7 days ago

What is Vascugen?

Vascugen is an induced pluripotent stem cell (iPSC) therapy company based in Indianapolis, Indiana, with a research and development facility that includes an integrated manufacturing facility for early-stage clinical manufacture of its products. The company focuses on developing engineered vascular cells to address ischemic disease conditions and serve as a platform for delivering therapeutic payloads in cardiovascular, solid tumor, and other indications. Their proprietary cell differentiation technology enables them to derive unique products using iPSC technology.

What specific cell therapy technology does Vascugen develop?

The company's lead program involves an iPSC-derived vasculogenic cell designed to forge new blood vessels in oxygen-starved tissues, particularly targeting patients at high risk for limb amputation and associated morbidity due to severe conditions caused by restricted blood flow. This approach aims to restore circulation by forming microvascular structures where standard treatments often fail. The technology is intended for patients suffering from critical conditions like critical limb ischemia and diabetic retinopathy.

How does Vascugen's vasculogenic approach differ from other ischemia treatments?

Vascugen's approach differs from other treatments by directly restoring blood flow through vasculogenesis, which forms new blood vessels, rather than relying on indirect mechanisms like growth factors or mesenchymal cells that stimulate angiogenesis. The company states that their vasculogenic cells have demonstrated the capacity to form new blood vessels in vivo in animal models of ischemic injury. This direct restoration of blood flow is the core of their therapeutic strategy.

What is the history of Vascugen's partnership with Indiana University?

The company was launched in 2018 in partnership with Indiana University (IU), a leading institution for medical research. Vascugen secured exclusive rights from IU to a broad technology portfolio developed in the laboratory of their scientific founder, Mervin C. Yoder, MD. This partnership provided access to two Nobel Prize-winning technologies: induced pluripotent stem cells (iPSCs) and gene modification.

What manufacturing standards and facilities does Vascugen use?

Vascugen operates out of an integrated R&D facility that includes a state-of-the-art cleanroom designed to iPSC industry standards. They have established dedicated quality assurance (QA) and a quality management system (eQMS) for compliance and product release. Where feasible, they deploy closed system manufacturing platforms in their processes to mitigate technology and tech transfer risks.

Who are the primary patients Vascugen aims to treat?

The company's target audience includes patients with severe forms of vascular disease, particularly those with critical limb ischemia (CLI) and diabetic retinopathy. Over 500,000 patients each year are diagnosed with CLI, which portends a grim prognosis with a 5-year cardiovascular mortality rate five times higher than a matched population without CLI. Vascugen aims to address these refractory conditions where patients have few or no treatment options.

What do reviewers say about Vascugen's products and service?

Vascugen's products are described by reviewers as having exceptional quality, with customers praising the outstanding customer service, prompt responses to questions, and on-time delivery. Some reviewers noted that the product quality surpassed expectations and that the service was impressive and helpful. The Trustburn rating is 3.9 out of 5 from 9 reviews, with most feedback being positive regarding product quality and service responsiveness.

What are the key features of Vascugen's cell replacement therapy?

The company utilizes an allogeneic, donor-independent cell replacement therapy that is directly capable of microvascular regeneration. Their technology portfolio includes access to iPSCs and gene modification, which are critical for advancing their therapeutic candidates. The goal is to translate discoveries into potent treatments for a range of vascular degenerative conditions.

What is Vascugen's overarching mission and focus?

Vascugen's mission is to revolutionize the standard of care for millions of patients suffering from severe conditions caused by restricted blood flow to tissues. They are focused on advancing cell therapies intended to restore function in tissues where there is a loss of blood flow, or ischemia. The company aims to develop advanced medicines for life-threatening conditions which often arise as a complication of diabetes or arterial disease.

What proprietary technologies and manufacturing processes does Vascugen employ?

Vascugen's technology is described as proprietary, with exclusive rights granted from Indiana University. The company emphasizes an integrated approach to advance therapeutic candidates from early R&D through to clinical (cGMP) manufacturing. This includes embedded quality assurance and a quality management system to ensure compliance and product release.

How does Vascugen manage its R&D and manufacturing operations?

The company's research and development facility includes an integrated manufacturing facility for early-stage clinical manufacture of their products. They aim to mitigate technology and tech transfer risks along the development chain by doing so. The facility is designed to iPSC industry standards, ensuring high-quality production of their engineered vascular cells.

What is the background of Vascugen's scientific leadership?

Vascugen's scientific founder, Mervin C. Yoder, MD, has spent over a decade on the discovery and characterization of unique endothelial cell populations that demonstrate the capacity to form new blood vessels in vivo. The company is translating these discoveries into therapeutic candidates targeting a range of vascular degenerative conditions. This expertise forms the foundation of their vasculogenic cell technology.

Where is Vascugen located?

Vascugen is located at 1800 north capitol avenue, Indianapolis, Indiana.

What is the official website of Vascugen?

The official website of Vascugen is vascugen.com.

How is Vascugen rated on Trustburn?

On Trustburn, Vascugen has a rating of 3.9 out of 5 based on 9 reviews.

AI-generated from reviews on this page. Verify anything important with the company directly.

News

No news yet. This is where the business shares its own updates and press.

Photos

No photos yet. Photos shared by reviewers will show up here.

Widgets

Boost your business trust by displaying a widget on your website — a simple way to convert your visitors into customers.

Get the widget for your site →

About Vascugen

Vascugen is an induced pluripotent stem cell (iPSC) therapy company advancing its novel vasculogenic cell technology to develop and manufacture engineered vascular cells. Our vasculogenic cells have the potential to directly address ischemic disease conditions and to serve as a novel platform for delivery of therapeutic payloads in cardiovascular, solid tumor, and other indications. Vascugen’s research and development facility includes an integrated manufacturing facility for early-stage clinical manufacture of our products.

Address
1800 north capitol avenue
Categories
Biotechnology